Hospira Told To Clean Up Manufacturing Process In India

Law360, New York (May 30, 2013, 1:11 PM EDT) -- Hospira Inc. is under fire from the U.S. Food and Drug Administration over allegedly unsanitary conditions at its pharmaceutical manufacturing facility in India that raise concerns about drug contamination, the company said in a regulatory filing Wednesday.

The FDA sent Hospira a warning letter informing the drugmaker of major violations of manufacturing regulations, including failing to properly clean surfaces and using damaged gloves when handling sterile products. The agency said it was particularly concerned because it witnessed similar violations during a recent inspection at Hospira's Rocky...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.